Skip to Content

Optaflu

Active Substance: influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) B/Phuket/3073/2013–like strain (B/Utah/9/2014, wild type)
Common Name: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
ATC Code: J07BB02
Marketing Authorisation Holder: Seqirus GmbH
Active Substance: influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) B/Phuket/3073/2013–like strain (B/Utah/9/2014, wild type)
Status: Withdrawn
Authorisation Date: 2007-06-01
Therapeutic Area: Influenza, Human Immunization
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications.

Optaflu should be used in accordance to official guidance.

The marketing authorisation for Optaflu has expired following the marketing authorisation holder's decision not to apply for a renewal.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide